Key Highlights

  • 7.4 million is the USD cash, cash equivalents and marketable securities balance reported by Lantern Pharma Inc. (NASDAQ:LTRN) at June 30, 2026, down from USD 10.1 million at December 31, 2025, a fall of 26.7%, calculated.
  • 0.57 is the loss per share for the second quarter of 2026, compared with 0.40 a year earlier, as a USD 3.6 million non-cash Warrant expense lifted the net loss to USD 7.1 million from USD 4.3 million.
  • 3.5 million is the USD operating loss in the second quarter of 2026, down 25% from USD 4.7 million, as Research and Development expense fell 42% to USD 1.8 million from USD 3.1 million.
  • 8.9 months is the median progression-free survival reported for nine EGFR exon 21 L858R patients who completed six cycles of LP-300 in the HARMONIC trial, with a hazard ratio of 0.37, exploratory data.

What Investors Expect From Lantern Pharma (NASDAQ:LTRN) on November 16, 2026

Lantern Pharma Inc. is scheduled to report third quarter 2026 results on November 16, 2026, covering the quarter ended September 30, 2026. As a clinical-stage oncology company with no product revenue, it will be judged on its loss and cash balance. In the second quarter of 2026 the net loss was USD 7.1 million, or 0.57 per share, and the six-month loss was USD 10.4 million, or 0.88 per share, versus USD 8.9 million, or 0.82 per share, a year earlier. In the third quarter of 2025 the company reported a loss of 0.42 per share.

The Rationale: Last Reported Quarter and Management Outlook for Lantern Pharma (NASDAQ:LTRN)

The second quarter of 2026 showed lower operating spending. Research and development expense was USD 1.8 million against USD 3.1 million, general and administrative expense rose 8% to USD 1.7 million from USD 1.6 million, and the loss from operations was USD 3.5 million. The wider net loss reflected about USD 3.6 million of warrant expense, mainly a non-cash fair-value increase tied to a higher stock price. Management has not issued numeric financial guidance. On the clinical side, the FDA raised no objections to HARMONIC protocol changes. The EMA cleared an investigator-initiated Phase 1b/2 bladder cancer trial of up to about 39 patients for LP-184, and the FDA cleared a planned Phase 1b/2 triple-negative breast cancer trial of about 40 patients.

Valuation, Liquidity and Risks for Lantern Pharma (NASDAQ:LTRN)

Cash, cash equivalents and marketable securities were about USD 7.4 million at June 30, 2026, consisting of roughly USD 6.7 million of cash and USD 0.7 million of marketable securities. A registered direct offering closed on May 14, 2026 raised about USD 4.4 million, and 12,759,146 shares were outstanding at June 30, 2026. The company did not state a cash runway in months and intends to pursue additional Capital raises. Risks include dilution, clinical outcomes and regulatory feedback.

Where Things Stand

Lantern Pharma Inc. (NASDAQ:LTRN) reports on November 16, 2026 with cash and marketable securities of USD 7.4 million at the last reported Balance Sheet date and a second quarter loss of 0.57 per share. Operating loss narrowed 25% to USD 3.5 million, calculated from reported figures of USD 3.5 million and USD 4.7 million. Investors will look for fresh updates on HARMONIC, the two LP-184 Phase 1b/2 trials and Open Medicine AI, and for any new financing steps to extend the operating runway. This preview is informational and is not Investment advice.